GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine segment. See why the stock is a Buy.

Explore Matthews International Corporation's restructuring efforts, asset sales, and challenges in reducing debt. Click for ...

Find insight on European pharmaceutical sector corporate bonds, GSK and more in the latest Market Talks covering Health Care.

The FTSE 100 index of leading shares has broken through 9,000 for the first time. That’s not as impressive as it ...

The Iseq All-Share index fell almost 1 per cent to 11,143.28. Ryanair stood out as a weak spot, sliding 2.1 per cent as ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and ...

The UK's FTSE 100 extended its winning streak to a fourth week on Friday, as investors looked past economic concerns to focus ...

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

GSK PLC GSK shares advanced 1.39% to £13.91 Thursday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.85% to 9,138.37. GSK PLC ...

GSK PLC GSK shares rose 1.78% to £13.72 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.42% to 9,061.49. GSK PLC ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.